Clinical trial
Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony…
NCT01757626 · Memorial Sloan Kettering Cancer Center, Other · Active, not recruiting
Key facts
| NCT number | NCT01757626 |
|---|---|
| Title | Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma |
| Official title | Phase I/II Study of Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | Y-mAbs Therapeutics Industry |
| Status | Active, not recruiting |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Neuroblastoma |
| Intervention type | Biological |
| Interventions | Hu3F8 With GM-CSF |
| Enrollment | 186 |
| Start date | Dec 1, 2012 |
| Primary completion | Dec 1, 2026 |
| Completion | Dec 1, 2026 |
| First posted | Dec 31, 2012 |
| Last update posted | Jan 7, 2026 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: